Guardant Health (GH) vs Henry Schein (HSIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Guardant Health (GH) has outperformed Henry Schein (HSIC) over the past year, gaining 165.3% versus a gain of 28.9%. Over five years, GH leads with a +65.7% price change compared with +8.0% for HSIC. Guardant Health is the larger company by market cap ($22.01 billion vs $9.19 billion), about 2.4 times the size.
Henry Schein converts more of its revenue into profit, with a net margin of 3.0% versus -42.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GH | HSIC |
|---|---|---|
| Share price | $164.04 | $82.49 |
| Market cap | $22.01B | $9.19B |
| 1-day change | -2.55% | -1.40% |
| YTD return | +64.80% | +10.69% |
| 1-year return | +165.34% | +28.95% |
| 5-year return | +65.68% | +8.03% |
| P/E ratio (TTM) | — | 24.05 |
| Forward P/E | — | 13.79 |
| EPS (TTM) | $-3.50 | $3.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $982.02M | $13.18B |
| Revenue growth (YoY) | +32.88% | +4.03% |
| Net income (latest FY) | $-416.28M | $398.00M |
| Gross margin | 64.46% | 31.14% |
| Operating margin | -44.53% | 4.95% |
| Net margin | -42.39% | 3.02% |
| 52-week high | $191.05 | $92.18 |
| 52-week low | $61.00 | $61.95 |
| Distance from 52-week high | -14.14% | -10.51% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +21.82% | +17.92% |
| Average volume | 2.02M | 1.20M |
| Shares outstanding | 134.20M | 111.45M |
| Employees | 2,490 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Guardant Health is about 2.4 times larger than Henry Schein by market value ($22.01B vs $9.19B).
- GH has outperformed HSIC by 136.4 percentage points over the past year.
- Henry Schein is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
- Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +4.03%).
About Guardant Health
GH stock →Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.
Health Care · Medical Specialities · 2,490 employees
About Henry Schein
HSIC stock →Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.
Health Care · Medical Specialities · 25,000 employees
GH vs HSIC FAQ
Which is bigger, Guardant Health or Henry Schein?
Guardant Health (GH) is larger, with a market capitalization of $22.01B compared with $9.19B for Henry Schein (HSIC).
Which stock has performed better over the past year, GH or HSIC?
GH returned +165.34% over the past 12 months, compared with +28.95% for HSIC (price return, excluding dividends). Past performance does not predict future results.
Are Guardant Health and Henry Schein in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.